Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Here’s What Happened

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY) gapped up before the market opened on Monday. The stock had previously closed at $13.0420, but opened at $13.67. Fresenius SE & Co. shares last traded at $13.6810, with a volume of 485 shares.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Citigroup reiterated a “buy” rating on shares of Fresenius SE & Co. in a report on Wednesday, October 28th. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company presently has an average rating of “Buy”.

Fresenius SE & Co. Trading Up 0.3%

The firm has a market cap of $30.65 billion, a price-to-earnings ratio of 13.70 and a beta of 0.63. The business’s fifty day moving average is $12.89 and its two-hundred day moving average is $12.86. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Equities analysts anticipate that Fresenius SE & Co. will post 1.04 earnings per share for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.